Acquisition adds 37 retail pharmacies, according to a statement.
- Deal is subject to approval by the Irish Competition and Consumer Protection Commission
- Deal will be earnings accretive from completion
- Deal expected to deliver a return on capital employed in line with Uniphar’s target rate of 12%-15% within three years
To view the source of this information, click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2022 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.